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1. INTRODUCTION 
 
1.1 Tumor immunology: from immuno-surveillance to tumor escape 
 
Understanding how the immune system affects cancer development and 
progression has been one of the most challenging questions in 
immunology.In the midpoint of the twentieth century, the concept that the 
immune system can recognize and destroy nascent transformed cells was 
embodied for the first time in the ‘cancer immunesurveillance’ hypothesis of 
Burnet and Thomas.They both speculated that lymphocytes acted as sentinels 
in recognizing and eliminating continuously arising, nascent transformed 
cells. Because of the absence of strong experimental evidence supporting the 
concept (not enough was understood about mouse models of 
immunodeficiency), this hypothesis was abandoned shortly afterwards. The 
concept was resurrected nearly three decades later when new data clearly 
showed the existence of cancer immunosurveillance and also indicated it as a 
component of a more general process called ‘cancer immunoediting’(Dunn et 
al., 2002). In cancer development, the immune system plays a dual role: on 
the one end it suppresses tumor growth by destroying cancer cells or by 
inhibiting their outgrowth, on the other end it also promotes tumor 
progression either by selecting for tumor cells that are more fit to survive in 
an immunocompetent host or by establishing conditions within the tumor 
microenvironment that facilitate tumor outgrowth (a phenomenon called 
‘immunoediting’). This conceptual framework integrates the immune 
system's dual host-protective and tumor-promoting roles. 
During cancer immunoediting, the host immune system shapes tumor fate in 
three phases, “elimination”, “equilibrium” and “escape”, through the 
activation of innate and adaptive immune mechanisms (Figure 1). 
 
The elimination phase is best described as an updated version of cancer 
immunosurveillance, in which the innate and adaptive immune systems work 
together to detect the presence of a developing tumor and destroy it before it 
becomes clinically apparent.  
Initiation of the antitumor immune response occurs when cells of the innate 
immune system become alerted to the presence of a growing tumor, at least 
in part owing to the local tissue disruption that occurs because of the stromal 
remodeling processes (Gopal, 2015). The consequent production of pro-
inflammatory molecules, together with chemokines that may be produced by 
the tumor cells themselves, leads to the recruitment of cells of the innate 
immune system (NKT, NK, γδ T cells, macrophages and dendritic cells). 
Infiltrating lymphocytes such as NKT, NK or γδ T cells recognize some 
structures on the transformed cells and are then stimulated to produce IFN-γ. 
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Tumor cells also express stress-induced molecules such as surface 
calreticulin, tumor antigens in context of MHC class I molecules, and/or 
NKG2D ligands recognized by CD8+ effector cells and NK cells, 
respectively. 
 
 
 
Figure 1. The three Es of cancer immunoediting (from Schreiber et al., 2011). 
In its most complex form, cancer immunoediting consists of three sequential phases: 
elimination, equilibrium, and escape. In the elimination phase, innate and adaptive immune 
response work in synergy to eliminate the rising transformed cells. The equilibrium phase 
provides evidence for a tumor-sculpting role of immunity. In this phase the immune system 
iteratively selects and/or promotes the generation of immune evasive tumor cell variants. 
When the immunologically sculpted tumor expands in an uncontrolled manner in the 
immunocompetent host the phase of escape is accomplished.  
 
 
The initial production of IFN-γ initiates a cascade of innate immune reactions 
leading to some tumor cell death by both immunologic and non immunologic 
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mechanisms. The INF-γ initially produced may induce a limited amount of 
tumor death by means of antiproliferative and apoptotic mechanisms. 
However, it also induces the production of some chemokines from the tumor 
cells themselves as well as from surrounding normal host tissues. Some of 
these chemokines have potent angiostatic capacities and thus they block the 
formation of new blood vessels within the tumor, enhancing tumor cell death. 
Furthermore, the transactivation of tumor-infiltrating NK cells and 
macrophages by reciprocal production of IFN- γ and IL-12 contributes to 
tumor cell death by mechanisms involving TRAIL, perforin and reactive 
oxygen and nitrogen intermediates. 
From dead tumor cells, a source of tumor antigens becomes available to the 
immature dendritic cells (DCs) recruited to the tumor site. These antigens 
might reflect one or more of the many mutated proteins that are typical of 
cancer (neo-antigens) or the products of non-mutated genes that are 
preferentially expressed by cancer cells (tumor associated antigens). 
The activated, antigen-bearing mature DCs then migrate to the draining 
lymphnode, where they induce the activation of naïve tumor-specific Th1 
CD4+ T cells. Th1 cells facilitate the development of tumor-specific CD8+ 
CTL induced via cross-presentation of antigenic tumor peptides on DC MHC 
class I molecules. Tumor-specific CD4+ and CD8+ T cells home to the tumor 
site, where the cytolytic T lymphocytes destroy the remaining antigen-
bearing tumor cells whose immunogenicity have been enhanced by exposure 
to locally produced IFN- γ (Figure 2). 
 
 
  
Figure 2. Cancer-immunity cycle. 
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The cancer-immunity cycle is a multistep process that involves (1) release of cancer cell 
antigens; (2) cancer antigen presentation; (3) priming and activation; (4) trafficking of T 
cells to the tumor; (5) infiltration of T cells into the tumor site; (6) recognition of cancer 
cells by T cells; (7) killing of cancer target cells (Chen and Mellman, 2013). 
 
When the elimination phase is successful, it represents the complete editing 
process without progression to the subsequent phases. 
If, however, rare tumor cell variants are not destroyed, they may survive the 
elimination phase and enter the equilibrium phase, in which the adaptive 
immune system prevents tumor cell outgrowth and also sculpts the 
immunogenicity of the tumor cells. 
In this process, lymphocytes and IFN- γ exert potent selection pressure on the 
tumor cells that is enough to contain, but not fully extinguish, a tumor bed 
containing many genetically unstable and rapidly mutating tumor cells. 
During this period of Darwinian selection, many of the original escape 
variants of the tumor cells are destroyed, but new variants arise carrying 
different mutations that provide them with increased resistance to immune 
attack. So, in the equilibrium phase, occult tumor cells not destroyed in the 
elimination phase are held in a state of tumor dormancy as a consequence of 
adaptive immune system activity and undergo “editing”. Recent work has 
demonstrated that T cells play a major role in shaping the immunogenicity of 
developing cancers and exert this effect by at least two mechanisms. First, T 
cells can shape tumor antigenicity/immunogenicity through an 
immunoselection process by destroying tumor cells that express strong 
tumor-specific mutant antigens, leaving behind tumor cells that either express 
weaker antigens or are incapable of expressing antigens (because of 
mutations in antigen processing or presentation)(Matsushita et al., 2012). 
Second, chronic T cell attack on a tumorhas been shown to silence expression 
of certain tumor-specific antigens through epigenetic mechanisms in a 
preclinical model (Dupage et al., 2012). 
 
When tumor cell variants selected in the equilibrium phase can grow in an 
immunologically intact environment they enter into the escape phase. The 
immune system fails to restrict tumor outgrowth and tumor cells emerge 
causing clinically apparent disease. 
Tumors escape immune attack by a variety of complementary mechanisms of 
immunosuppression, many of which operate in parallel: 
 
 Reduced immune recognition: tumor cells can directly escape T-cell 
recognition by downregulating MHC class I, class I-like, or co-stimulatory 
molecules or by disabling other components of the antigen processing 
machinery. 
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 Increased resistance or survival (such as increased expression of STAT-3 
or anti-apoptotic molecule Bcl2). 
 Development of an immunosuppressive tumor microenvironment. 
o Among paracrine mediators, release of PGE2, arginase and IDO (all 
T-cell suppressors), and the release of VEGF (triggered in part by 
intratumoral hypoxia), exert multiple direct and indirect 
immunosuppressive activities. These mediators may function indirectly 
inhibiting T-cell diapedesis from the vasculature into the tumor bed or 
directly suppressing effector T-cell activation while enhancing the 
function of regulatory T cells (Treg). 
o In addition, tumor cells may upregulate surface ligands, including PD-
L1, PD-L2 and other ligands that engage receptors on the surfaces of 
activated T cells (PD-1), causing T-cell anergy or exhaustion. 
 Recruitment of a variety of leukocyte subsets infiltrating tumors able to 
suppress T-cell function. In addition to Treg cells (the accumulation of 
which in tumors correlates with poor prognostic outcome), other 
suppressive lymphocyte subsets have been reported. They include IL-10 
producing B cells and B regulatory cells, type II NKT cells, NK cells and 
γδ T cells. Myeloid lineage cells also promote immune suppression in 
tumors. Among these, myeloid-derived suppressor cells (MDSC) suppress 
T andNK cell activation, probably through several mechanisms including 
nitric oxide, reactive oxidative species, arginase, IL-10 andTGF-β; 
thereare also reports that MDSCs may specifically induce the expansion of 
Treg cells.  
 
 
1.2 Vaccines in cancer therapy 
 
1.2.1 Tumor-associated antigens 
Cancer immunotherapy seeks to exploit the host’s immune system to 
eliminate cancer cells. In this context, cancer antigens play a critical role, as 
they are responsible for triggering a cancer specific immune response.At the 
core of the design of immunotherapy strategies lies the fact that cancer 
patients can produce T lymphocytes that recognize tumor-specific antigens. 
Ideally, cancer antigens should be highly immunogenic to induce strong 
immune responses and only be expressed by malignant cells for specific 
tumor killing. However, normal tissues may also express some. For this 
reason, human tumor antigens can be grouped in two main classes: 1) 
antigens of high tumoral specificity and 2) antigens of low tumoural 
specificity (Cooley et al 2014). 
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Three types of tumor antigens have the potential to elicit immune responses 
that are strictly tumor specific: 1) oncoviral antigens, 2) mutated antigens 
and 3) cancer-testis antigens. Instead, antigens of low tumor specificity 
include 4) differentiation antigens and 5) overexpressed/ accumulated 
antigens (Figure 3). 
 
1) Approximately 12% of all human cancers worldwide are associated with 
oncogenic viruses. Human tumor viruses belong to a number of virus 
families, including the RNA virus families Retroviridae and Flaviviridae and 
the DNA virus families Hepadnaviridae, Herpesviridae and Papillomaviridae 
(McLaughlin-Drubin and Munger, 2008). They are associated to the onset of 
an important subset of human tumors, including cervical carcinoma, 
hepatocarcinoma, nasopharyngeal carcinoma and adult T cell leukemia 
(Parkin, 2006). 
Even though human oncogenic viruses belong to different virus families and 
utilize diverse strategies to contribute to cancer development, they share 
many common features. One key feature is the tendency to establish long-
term persistent infections. Consequently, they have evolved different 
strategies for evading the host immune response, which would otherwise 
clear the virus during these persistent infections. 
Immunocompetent individuals normally mount a potent cytotoxic T-cell 
(CTL) response against infected cells expressing viral epitopes. However, 
oncogenic viruses generally avoid CTL surveillance by establishing latency 
in host cells. γ-herpesviruses express genes during the latency which can 
block TNF-induced pro-apoptotic signals generated by cell-mediated 
cytotoxic responses. Latent γ-herpesviruses remain under tight transcriptional 
regulation by NF-κB and histone deacetylase enzymes (HDACs). Disruption 
of viral latency in γ-herpesvirus lymphomas using the NF-κB and HDAC 
inhibitors results in lytic reactivation and cell death (Ramos and Lossos, 
2011). Likewise, the chronic antigenic stimulation in HPV infections 
supports the establishment of an immunosuppressive microenvironment that 
triggers the transition from normal epithelium to cervical intra-epithelial 
neoplasia (CIN) and vulvar intraepithelial neoplasia (VIN) as well as their 
subsequent progression to invasive squamous cell carcinoma. In particular, 
IDO+ cells, FOXP3+ T cells, and TGFβ+ T cells increase across the disease 
spectrum in parallel with a sharp decline in IFN-γ+ cells in invasive cancer 
(Kobayashi et al., 2008). 
2) Mutated genes greatly contribute to the immunogenicity of human tumors. 
Gene mutations produce new antigenic peptides by changing one amino acid, 
by altering the phase of the reading frame or by extending the coding 
sequence beyond the normal stop codon. Due to their unique nature of being 
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expressed only on tumors and not on any other normal tissues, these tumor-
specific TAAs can be recognized as non-self and not be subjected to central 
immune tolerance. These mutated proteins may play a critical role in the 
oncogenic process as products of mutated oncogenes or tumor suppressor 
genes and therefore survive immune selection in order to maintain tumor 
growth and proliferation. Mutated CDK4 is an example of tumor antigens 
proved to be oncogenic. A point mutation in CDK4 results in the loss of 
binding of CDK4 to the inhibitor INK4A with a consequent disrupting of the 
cell cycle regulation (Plaen et al., 1995). 
These type of mutations that confer a selective growth advantage, thus 
promoting cancer development, are commonly defined ‘driver mutations’. 
Cancer cells also develop a large number of mutations that do not provide a 
growth advantage and are therefore called ‘passenger mutations’. In most 
cancers, there are many more passenger mutations than driver mutations, 
with the latter ones more frequently giving rise to the so-called neo-antigens 
(discussed in 1.4.1). 
 
3) Cancer/testis (CT) antigens are a category of tumor antigens with normal 
expression restricted to male germ cells in the testis but not in adult somatic 
tissues. In some cases, CT antigens are also expressed in ovary and in 
trophoblast. In malignancy, this gene regulation is disrupted, resulting in CT 
antigen expression in a proportion of tumors of various types.The first cancer 
antigen reported that could be recognized by T cells, MAGE-A1, belongs to 
this class (van der Bruggen et al., 1991). 
Cancer-germline genes are an important source of tumor-specific antigens, 
with more than 60 cancer-germline genes having been identified. The 
mechanism that leads to the activation of these genes in tumor cells involves 
the demethylation of their promoter, which is methylated in all normal cells 
except in germline cells (De Smet et al., 1996). 
 
4) Differentiation antigens are cell type specific and shared between tumors 
and the normal tissue of origin (Buonaguro et al., 2011). For example, both 
melanoma and normal melanocytes express GP100, Tyrosinase, and Melan-
A/MART-1. Other differentiation antigens include PSA, Mammoglobin-A, 
and carcinoembryonic antigen (CEA) overexpressed in prostate cancer, 
breast carcinoma, and colon cancer respectively. 
 
5) Some proteins shared by both normal and tumor cells may display 
overexpression only in cancer cells thus providing an opportunity for a 
specific T cell response. This is because a threshold level of antigen is 
required for recognition by T cells. If tumor cells present an amount of 
peptide–HLA complexes that is above the threshold of T cell activation and if 
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normal cells do not, a specific antitumor T cell response could occur. In this 
way, over-expression by malignant cells overrides tolerance and triggers T 
cell activation. An example of overexpressed tumor antigen is the oncogene 
and growth factor receptor ERBB2 (also known as HER2 and NEU) which is 
overexpressed in many epithelial tumors, including ovarian and breast 
carcinomas, owing to increased transcription and to gene amplification (Ross 
et al., 1998). 
 
Figure 3. Classes of human tumor antigens recognized byT lymphocytes. 
a. Oncoviral antigens, mutated antigens and cancer-testis antigens show high tumor 
specificity. Point mutations can modify a peptide that already binds to the major 
histocompatibility complex or can enable a non-binding peptide to bind. Cancer-germline 
genes are selectively expressed in tumors and germline cells because of DNA demethylation. 
However, their antigens are not present on germline cells because of the lack of HLA 
molecules. b. Antigens of low tumor specificity include differentiation antigens and 
overexpressed/ accumulated antigens. In the figure, a melanocyte-specific gene is used as an 
example of tissue-specific gene expression. Both tumor cells and the normal tissue of origin 
(melanocytes) share the encoded protein. In the last panel, overexpression of particular 
proteins, such as ERBB2, beyond threshold levels can also trigger an antitumor immune 
response.  
 
 
1.2.2 Therapeutic cancer vaccines 
Traditionally, vaccines have been used as a preventive measure against 
infectious diseases, triggering the immune system to produce neutralizing 
antibodies against specific pathogen antigens. More recently, vaccines have 
been applied as therapeutic strategies, aiming to induce immune system to 
activate cytotoxic T cells against infected cells and cancer. However, 
therapeutic vaccination against established diseases has proven much more 
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challenging than prophylactic vaccination against infectious diseases, 
because the vaccine intervention must overcome the hurdles posed by 
immune evasion by having to antagonize an immune system that has been 
restrained by tolerizing or polarizing mechanisms that sustain the disease in a 
misguided attempt at self-tolerance (Melief et al., 2015). 
The idea of a therapeutic cancer vaccine originated with the discovery that 
patients can harbor CD8+ and CD4+ T cells specific for cancer antigens 
expressed in their tumors (Boon at al., 2006). Therefore, vaccination might 
reasonably be expected to amplify the frequency and strength of these pre-
existing responses against tumor antigens or perhaps induce some de novo 
reactivities. 
Based on their format/content, cancer vaccines may be classified into several 
major categories, which include cell based vaccines (tumor cell lysates, 
irradiated whole tumor cells, DCs), protein/peptide vaccines, and genetic 
vaccines (DNA, RNA and viral vectors) (Guo et al., 2013). Their 
development is based on the concept that the introduction of various tumor 
antigens into the host would facilitate immune mediated clearance of tumor 
cells. Ideally, therapeutic vaccination aims at expanding high-avidity CD8+ T 
cells that can differentiate into CTLs able to kill cancer cells and to generate 
long-lived memory CD8+T cells. This could be accomplished through either 
the priming of naïve T cells or the reprogramming of memory T cells that 
differentiate earlier in an environment not conducive to the generation of 
potent cytotoxic T cells. Indeed, cancer is a chronic disease and, as such, it is 
associated with skewed T cell memory, chronically activated and anergic 
CD8+ T cells that express programmed cell death 1 (PD-1) (Freeman et al., 
2006). In addition, vaccination should lead to the generation of long-lived 
memory CD8+ T cells that will act to prevent relapse (Figure 4). 
 
 
Figure 4. Therapeutic vaccines act to generate protective CD8+ T cell immunity (from 
Palucka and Banchereau, 2013). 
Introduction 
 
10 
 
Therapeutic vaccines are expected to prime new T cells and induce a transition from 
chronically activated non-protective CD8+ T cells to healthy CD8+ T cells able to (1) 
generate CTLs that reject cancer and (2) provide long-lived memory CD8+ T, thereby 
preventing relapse. 
 
1.2.3  Genetic cancer vaccines 
Therapeutic vaccines have two objectives: priming antigen-specific T cells 
and reprogramming memory T cells. In this context, genetic vaccines 
represents a highly promising approach. 
Genetic vaccination exploits the use of viral or bacterial vectors or nucleic 
acids to deliver one or more antigens in vivo. One major advantage of genetic 
vaccines is the easy delivery of multiple antigens in one vaccine and their 
ability to activate various arms of the immune system (Aurisicchio and 
Ciliberto, 2012). 
 
 DNA vaccines consists of bacterial plasmid DNA into which specific 
sequences are incorporated under the control of an eukaryotic promoter. 
Genes in DNA vaccines can encode different antigens as well as various 
immunomodulatory molecules to manipulate the resulting immune response, 
after transduction into the target cells and subsequent in vivo expression by 
the host’s gene expression machinery. 
 
DNA vaccines were shown to be able to trigger both innate and adaptive 
immune response. The ability to stimulate the innate immune system arises 
from the bacterial origin of the backbone (Rice et al., 2008). The bacterial 
DNA appears to act as a pathogen-associated molecular pattern able to 
stimulate cells through Toll-like receptors (TLRs). Specifically, the 
hypomethilated CpG dinucleotides motif that is common in bacterial DNA, 
but rare in mammalian DNA, interacts with TLR9 expressed in immune cells, 
such as dendritic cells, B cells, and NK cells. Activation of TLR9 leads to a 
cascade of pro-inflammatory responses and results in the production of 
various cytokines. The local inflammation and increased production of 
cytokines from the innate immune responses can attract and activate 
additional immune cells, such as lymphocytes, and enhance subsequent 
antigen-specific immune responses. 
 
DNA vaccines are delivered intradermically or more commonly by 
intramuscular injection, resulting in the transfection of keratinocytes or 
myocytes, respectively.  
In the muscle, transfected myocytes express the vaccine-encoded antigens 
and act as a target for immune effector cells. In addition, they can also 
upregulate expression of MHC class I and co-stimulatory molecules, with 
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production of cytokines and chemokines. Consequent inflammation and 
production of cytokines attract professional APCs, like dendritic cells, to the 
transfection sites.  
APCs have a dominant role in the induction of immunity of DNA vaccines 
by presenting vaccine-derived endogenous peptides on MHC I molecules. 
APCs can ‘capture’ these antigens by direct transfection or most commonly 
by cross presentation for example, owing to APC engulfment of apoptotic 
transfected cells. In addition, APCs mediate the display of peptides on MHC 
II molecules after secreted protein antigens from transfected cells are 
captured and processed within the endocytic pathway. 
Antigen-loaded APCs travel to the draining lymph node via the afferent 
lymphatic vessel where they present peptide antigens to naïve T cells via 
MHC and the T cell receptor (TCR) in combination with co-stimulatory 
molecules, initiating an immune response and expansion of T cells. In 
response to peptide-bound MHC molecules and co-stimulatory secondary 
signals, activated CD4 T helper cells secrete cytokines during cell-to-cell 
interaction with B cells and bind to co-stimulatory molecules that are 
required for B cell activation (Figure 5). 
 
The use of DNA plasmids in cancer immunotherapy offers several 
advantages. In addition to their safety, DNA vaccines allows for simple and 
flexible design, encoding wide range of antigens and immunomodulatory 
molecules. DNA vaccines are heat stable, easily stored and perfect for large 
scale production (Yang et al., 2014). 
However, despite the promising features of DNA vaccines, they have been 
found to elicit immune responses less than other types of vaccines, including 
peptide vaccines, cellular vaccines, viral vector vaccines, and RNA vaccines. 
The relatively poor immunogenicity of DNA vaccines combines with other 
disadvantages: inefficient delivery of DNA into human cells, the need for 
DNA to cross both cell and nuclear membranes and be transcribed in order to 
allow for expression of the encoded antigen. Some of these considerations 
have driven a shift away from DNA vaccines and towards RNA vaccines. 
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Figure 5. Induction of cellular and humoral immunity by DNA vaccines 
The optimized gene sequence of interest is inserted into a plasmid backbone, purified, and 
then delivered to the inoculation site. Using the host cellular machinery, the plasmid enters 
the nucleus of transfected myocytes (1) and of resident antigen presenting cells (APCs) (2). 
Here, the plasmid components initiate gene transcription, which is followed by protein 
production in the cytoplasm and the consequent formation of foreign antigens, that can 
become the subject of immune surveillance in the context of both major histocompatibility 
complex class I (MHC I) and MHC II proteins. The presentation of vaccine-derived 
endogenous peptides on MHC I molecules by APCs can follow either direct APCs 
transfection by the plasmid vaccine (2) or cross-presentation of cell-associated exogenous 
antigens (3). In addition, APCs can capture secreted protein antigens that have been shed 
from transfected cell, process them within the endocytic pathway and finally display peptides 
on MHC II molecules (4). Antigen-loaded APCs travel to the draining lymph node via the 
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afferent lymphatic vessel (5) where they present peptide antigens to naïve T cells via MHC 
and the T cell receptor (TCR) in combination with co-stimulatory molecules, providing the 
necessary secondary signals to initiate an immune response and expansion of T cells (6). In 
turn activated CD4 T helper cells promote B cell activation (7). ‘Armed’ lymphocytes can 
finally leave the draining lymph node through the efferent lymphatic system (8).Kutzler and 
Weiner, 2008 
 
 
 RNA vaccines consist in messenger RNA (mRNA) synthesized by in vitro 
transcription using a bacteriophage RNA polymerase and template DNA that 
encodes the antigen(s) of interest (McNamara et al., 2015). Once 
administered and internalized by host cells, the mRNA transcripts are 
translated directly in the cytoplasm and then, like DNA vaccines, the 
resulting antigens are presented to APC by major histocompatibility complex 
(MHC) class I and II proteins, with consequent induction of T cell-mediated 
immune responses. Alternatively, RNA vaccines can be constructed for the 
efficient production and secretion (or cell-surface expression) of extracellular 
antigens to stimulate B cell responses and antigen-specific antibody 
production. The effectiveness of RNA vaccines may also be related to the 
fact that RNA is known to be a potent stimulator of innate immunity (Ulmer 
et al., 2012). 
Several techniques have been developed to improve the inherent instability of 
mRNA and translational efficiency and to optimize RNA vaccine delivery.  
 
 One approach to induce a potent and targeted anti-tumor response is to use 
viruses to deliver tumor antigens to cells of the immune system. 
Viral vectors are an attractive choice of antigen delivery system for cancer 
immunotherapy since they mimic a natural infection and provide potent 
danger signals, which are known to be important for the induction of an 
immune response (Harrop and Carroll, 2006).They enable intracellular 
antigen expression and induce a robust cytotoxic T lymphocyte (CTL) 
response, leading to the elimination of diseased cells. 
Despite their efficacy, viral vectors present unavoidable problems that need 
to be addressed. Viral vector-based vaccines require assessment of efficacy 
and safety, including immunogenicity, genetic stability, ability to evade pre-
existing immunity, replication deficiency or attenuation, and genotoxicity. 
For a high biological safety level, non- (or low-) pathogenic viruses are often 
selected (Ura et al., 2014). 
Different viral vectors have been evaluated in cancer immunotherapy: 
adenoviruses, Adeno-Associated Virus (AAV), alphaviruses, flaviviruses, 
lentiviruses, measles virus, rhabdoviruses, retroviruses and Vaccinia Virus 
(VV) (Lundstrom, 2016). 
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The intrinsic properties of each virus have distinct advantages and 
disadvantages, which can determine their applicability in a particular 
therapeutic setting. 
 
 
1.2.4 Adeno vector based cancer vaccines 
Adenovirus vectors (Ads) are one of the most effective carriers for delivery 
of foreign antigens into the host cells. Ads have a large genome size and 
allow cloning of expression cassette for large antigens (ie: over 2000 amino 
acids). Furthermore, Ads do not integrate the viral genomic DNA into the 
hosts’ genome, which reduces the risk of insertion mutagenesis (Zhang and 
Zou, 2016). Compared with other viral vectors, Ads are highly immunogenic 
and can induce robust adaptive immune responses, offering one of the most 
powerful technologies for cancer vaccine applications. 
Adenoviruses are double-stranded DNA viruses with a genome of ~34–43 kb, 
with two inverted terminal repeats at both ends as origins for DNA 
replication. The genes that Ads express during the life cycle are generally 
clustered in early genes and late genes. The early genes include E1A, E1B, 
E2, E3 and E4, and they are mainly responsible for facilitating the replication 
of Ads by changing the expression levels of related host genes. The early 
genes can be further classified into two types: the immediate early genes 
(E1A) and the delayed early genes (E1B, E2, E3 and E4).  
The E1A gene is transcribed first and, with the help of cellular factors, 
activates transcription of the other viral genes. Deletion of E1A renders the 
virus replication-defective. E1A stimulates viral DNA synthesis, dysregulates 
cell-cycle control, promotes apoptosis and plays a role in immunoevasion by 
inhibiting the activity of STAT1, which is needed for activation of interferon-
responsive genes.  
While E1A proteins promote apoptosis, E1B proteins have antiapoptotic 
functions. E1B polypeptides turn off host cell protein synthesis and help to 
stabilize, transport, and translate selectively viral RNA. 
The E2 unit encodes DNA-binding proteins and a polymerase and is 
essentialfor viral replication.  
E3 proteins allow the virus to escape immunosurveillance by different 
mechanisms: i) by reducing expression of major histocompatibility complex 
(MHC) class I determinants; ii) by direct binding to the groove of MHC class 
I molecules preventing binding and export to the cell surface of peptides; iii) 
by associating with TAP and thereby reducing efficient transport of peptides 
derived from proteolytic cleavage of de novo synthesized viral proteins from 
the cytoplasm tothe endoplasmic reticulum where they can associate with 
MHC class I molecules. 
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The E4 transcription unit encodes seven polypeptides, which affect viral 
transcription and a number ofhost cell functions including cell proliferation 
and apoptosis, in part by promoting degradation of p53. E4 is essential for 
nuclear export of viral RNA.  
The late genes (L1-L5) are mainly responsible for the lysis of the host cells, 
assembly and release of the virions. 
Ad virions mainly comprise two types of proteins: the capsid proteins and the 
core proteins. The core proteins mainly include proteins V, VII, X, and they 
mainly function as the DNA-associated proteins. The capsid proteins 
comprise Hexon, Penton, fiber, IIIa, VIII and IX. 
Ads are isolated from different mammalian species, such as humans, dogs, 
sheep, bovines and non human primates. Among all, the human Ads and 
chimpanzee Ads are widely used in research or clinical studies. They have a 
broad tropism infecting a variety of dividing and non-dividing cells. They can 
be grown in human HEK293 cells and purified by CsCl gradient 
ultracentrifugation or chromatography, making them attractive for clinical 
use. 
 
Adenoviruses are useful vectors for genetic vaccine delivery. To insert 
transgenes of interest viral E1 and E3 genes are commonly deleted and 
depending on space necessity, there is the possibility to delete also the E4 
gene. By deletion of these genomic regions, the virus loses self-replication 
capacity, becoming replication-defective. This arrangement increases their 
predictability of their immunization properties and reduces unwanted side 
effects.  
The most commonly used adenoviral vectors as genetic vaccines are derived 
from human adenovirus serotype 5. In particular, head-to-head comparisons 
with other genetic vaccine vectors (ie.: poxviruses, lentiviruses, alpha virus-
based vectors and naked DNA) in animal models and the results obtained in 
human clinical trials, clearly showed that Ad5-based vectors currently 
represent one of the most potent delivery system for eliciting a CD8+ T cell 
response against the encoded antigen(s). However, high titers of anti Ad5 
neutralizing antibodies are commonly present in human population, 
impairing the immunogenicity of Ad5-based vaccines in humans. 
To overcome this drawback, other human Adenovirus vectors based on rare 
serotypes such as Ad11, Ad24, Ad26, Ad34, Ad35, Ad48, Ad49, and Ad50 
have been proposed as potential alternatives to Ad5 because antibodies 
present in humans rarely neutralize them. However, they showed lower 
immunological potency than Ad5 in mice and non-human primates. Another 
approach is to use non-human Adenoviruses. Indeed, Colloca et al., (2012) 
generated a large collection of replication defective vectors based on Ad 
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isolated from chimpanzees. Functional screenings to assess growth capability 
in packaging cell lines as HEK293 and PER.C6, immunological potency in 
mice and non-human primates and sensitivity to neutralizing antibodies 
present in humans allowed the identification of novel vaccine carriers 
inducing potent cellular immunity, suitable for vaccine delivery in humans. 
Among the large number of candidates screened for immunological potency 
by dose/response in mice, some ChAds were identified which showed 
immunological potency equivalent to Ad5 (ChAd3, ChAd63, ChAd83, 
PanAd1, PanAd2 and PanAd3). Importantly, the high level of 
immunogenicity of the top ranking ChAd3 and PanAd3 was confirmed in 
non-human primates, where they induced a level of T-cell response 
comparable to that of Ad5 even at low dose. 
 
1.3 The blockade of immune checkpoints in cancer immunotherapy 
1.3.1 Immune checkpoint receptors 
The initiation and progression of immune responses are fine-tuned by a 
highly complex array of cytokines, chemokines, toll-like receptors and 
costimulatory molecules. Equally complex is the diversity of pathways and 
mechanisms employed by the immune system to regulate and/or terminate 
ongoing immune responses. When the regulatory mechanisms somehow fail, 
normal immune homeostasis is impaired leading to disastrous consequences 
to the host, as the onset of autoimmunity. 
Co-stimulatory and co-inhibitory immune checkpoint receptors are critical 
modulators of the immune system, as they determine the functional outcome 
of T cell receptor (TCR) signalling. 
Following recognition of cognate peptide–MHC complexes on APCs by the 
TCR, co-signalling receptors often colocalize with TCR molecules at the 
immunological synapse, where they synergize with TCR signalling to 
promote (co-stimulatory receptors) or inhibit (co-inhibitory receptors) T cell 
activation and function (Figure 6). 
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Figure 6. Multiple co-stimulatory and inhibitory interactions regulate T cell responses 
(from Pardoll, 2012). 
Various ligand–receptor interactions between T cells and antigen-presenting cells (APCs) 
regulate the T cell response to antigen after the recognition of the cognate antigen through 
the TCR. These responses can occur at the initiation of T cell responses in lymph nodes or in 
peripheral tissues or tumors, where effector responses are regulated. 
 
 
In this interactive environment, the repertoire of co-signalling receptors 
expressed on T cells is highly versatile and responsive to changes in 
overlapping spatiotemporal fashion. The costimulatory receptor CD28 and 
the inhibitory receptor CTLA-4 (cytotoxic T-lymphocyte-associated antigen 
4) are a pivotal example. They bind the same ligands but they display distinct 
kinetics of expression, in order to modulate TCR signalling during the 
immune response (Intlekofer and Thompson, 2013). 
 
The discovery of CD28 stimulatory receptor gave molecular confirmation to 
the theory according to which the TCR engagement is not itself sufficient to 
enact T cell clonal expansion and differentiation whereas a second signal is 
pivotal to drive lymphocyte clonal expansion. 
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CD28 is constitutively expressed on the surface of resting and activated T 
cells, while its ligands CD80 (or B7-1) and CD86 (or B7-2) belonging to the 
B7 ligands are expressed of the surface of APCs. The interaction between 
them provides a second signal to promote T cell activation, proliferation, 
survival and activation of effector functions. 
 
The inhibitory receptor CTLA-4, expressed on the surface of activated T cells 
shares significant homology to CD28 and bounds the same B7 ligands, but 
their interaction counteracts CD28-mediated costimulatory signals and 
impairs the activation of T cells.  
This opposed action is explained by a unique spatiotemporal regulation of 
CTLA-4.In resting T cells, CTLA-4 exhibits minimal expression and a 
peculiar pattern of intracellular localization and trafficking. It resides mostly 
within intracellular vesicles of the trans-Golgi network and endosomal 
compartments. Upon TCR engagement, CTLA-4 expression is induced, and 
intracellular vesicles containing CTLA-4 undergo relocalization to the 
immune synapse. At the cell surface, CTLA-4 competes with CD28 for 
access to B7 ligands. Compared with CD28, CTLA-4 has higher affinity and 
avidity for B7 ligands, which has been attributed to homodimer formation by 
CTLA-4 that allows for bivalent binding of B7 molecules, in contrast to the 
monovalent binding of B7 ligands by CD28.  
The definitive role of CTLA-4 as a major negative regulator of T-cell 
activation was established with the description of CTLA-4−/− mice. They 
succumbed at three-to-four weeks of age from massive lymphoproliferation 
within the spleen and lymph nodes and end-organ infiltration by activated 
lymphocytes (Tivol et al., 1995). 
Of note, CTLA-4 is constitutively expressed on Foxp3+ Treg cells that may 
use CTLA-4 to mediate suppression of T effector cells. The finding that 
conditional deletion of CTLA-4 in Tregs, but not in other cell types, results in 
impaired Treg functions appears to support this notion (Wing et al., 2008).  
 
CTLA-4 together with PD-1 (discussed in section 1.3.2) are the two negative 
checkpoint regulators that have been most actively studied. However, 
multiple additional inhibitory receptors have been discovered in the recent 
years. TIM-3 (T-cell immunoglobulin and mucin-containing protein 3), 
LAG-3 (lymphocyte-activated gene-3), TIGIT (T cell immunoreceptor with 
Ig and ITIM domains), BTLA (B and T lymphocyte attenuator) and VISTA 
(V-domain Ig suppressor of T cell activation) represent the main examples. 
Among them Lag-3, Tim-3 and TIGIT represent the next generation of co-
inhibitory receptors to be translated to the clinic since they are highly 
expressed on dysfunctional or exhausted T cells in chronic diseases such as 
chronic viral infection and cancer.  
Introduction 
 
19 
 
A comparison concerning expression, signaling mofits and ligands between 
them is briefly summarized in Table 1. 
 
 
Table 1. Comparison of Lag-3, Tim-3 and TIGIT (from Anderson et al., 2015). 
 
 
Several observations proved that these receptors have been shown to be 
important immune regulators in autoimmunity. Lag-3 plays a protective role 
in autoimmunity by dampening T helper (Th) cell responses directly through 
engagement of MHC-II. In addition, Lag-3 indirectly inhibits effector T cell 
responses via promotion of Treg-cell- and Tr1-cell-mediated suppression. In 
autoimmune diseases such as multiple sclerosis, Tim-3 is under-expressed on 
pathogenic Th1 cells. IFN-β therapy can increase Tim-3 on antigen-specific 
T cells directly or indirectly via promotion of IL-27 production from local 
antigen-presenting cells. Increased expression of Tim-3 is associated with 
reduction in disease relapses. TIGIT inhibits auto-pathogenic Th1/Th17 T 
cell responses through three different pathways: (1) TIGIT directly inhibits T 
cell activation and expansion; (2) TIGIT expressing effector and regulatory T 
cells engage CD155 on APCs thereby inducing tolerogenic APCs that secrete 
IL-10; (3) TIGIT promotes Treg-cell-mediated suppression through the 
induction of IL-10 and Fgl2, which potently and selectively suppress Th1 and 
Th17 cell responses. 
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1.3.2 PD-1/PD-L1 pathway 
Immune checkpoints refer to a plethora of inhibitory pathways hardwired into 
the immune system that are crucial for maintaining self-tolerance and 
modulating the duration and amplitude of physiological immune responses in 
peripheral tissues in order to minimize collateral tissue damage. Among the 
inhibitory immune mediators, the pathway consisting of the programed cell 
death 1 (PD-1) receptor (CD279) and its ligands PD-L1 (B7-H1, CD274) and 
PD-L2 (B7-DC, CD273) plays an important role in the induction and 
maintenance of peripheral tolerance and for the maintenance of the stability 
and the integrity of T cells. PD-1’s immune-inhibitory function was 
elucidated by characterizing the autoimmune phenotype of PD-1–deficient 
mice, in which PD-1 deficiency leads to a loss of peripheral tolerance and the 
subsequent development of autoimmunity. PD-1–deficient mice develop 
different autoimmune diseases depending on their genetic background: 
C57BL/6-Pdcd1−/− mice develop lupus-like arthritis and glomerulonephritis 
with IgG3 and C3 deposits (Nishimura et al., 1999). BALB/c-Pdcd1−/− mice 
develop fetal dilated cardiomyopathy with a concomitant production of 
autoantibodies against cardiac troponin I (Nishimura et al., 2001). 
 
The PD-1:PD-L1/L2 pathway also mediates potent inhibitory signals to 
hinder the proliferation and function of T effector cells. Similarly to 
CD80/CTLA-4, PD-L1/PD-1 are antagonists of CD80/CD28 co-stimulation. 
Engagement of PD-1 by its ligands PD-L1 or PD-L2 strongly counteracts 
TCR signal transduction and CD28 co-stimulation, transducing a signal that 
inhibits T cell proliferation, cytokine production, and cytolytic function.  
 
Programmed death 1 (PD-1) receptor is a type I transmembrane protein 
preferentially expressed on activated CD4+ and CD8+ T cells, B cells, 
monocytes, natural killer (NK) cells, and dendritic cells (DCs). PD-1 consists 
of a single N-terminal IgV-like domain, an approximately 20 amino acid 
stalk separating the IgV domain from the plasma membrane, a 
transmembrane domain, and a cytoplasmic tail containing tyrosine-based 
signaling motifs: an immunoreceptor tyrosine-based inhibitory motif (ITIM) 
followed by an immunoreceptor tyrosine-based switch motif (ITSM). Both 
these motifs are implicated in PD-1 immunosuppressive effects, even if the 
ITSM appears to be the most important for mediating PD-1 suppression of 
lymphocyte activation (Chemnitz et al., 2004). 
Upon binding to its ligands, PD-1 becomes phosphorylated on intracellular 
tyrosine residues within ITIM. Subsequently, protein phosphatases, such as 
SHP-2 are recruited to bind to the ITSM, become activated and inhibit 
proximal TCR signaling events (Sheppard et al., 2004) (Figure 7). 
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Figure 7.  PD-1-dependent inhibitory mechanisms. (from Arasanz et al., 2017) 
PD-1 mediates its immunosuppressive activity through direct and indirect inhibitory 
mechanisms over TCR signalling and T cell proliferation, by inhibiting membrane-proximal 
T cell signaling events. (A) The direct inhibition of TCR signaling depends on the 
recruitment of SHP1 and SHP2 phosphatases to the tyrosine-based signaling motifs ITIM 
and ITSM. These phosphatases interfere with TCR signal transduction and CD28 co-
stimulation by inhibiting ZAP70 and PI3K activities, respectively.(B)PD-L1 engaged PD-1 
exerts an indirect inhibitory control over CD28 co-stimulation by reducing the expression 
levels and activities of CK2. As a result, active PTEN eliminates PIP3, shutting offAKT 
activation.Consequently,cell growth and survival is inhibited, because lymphocytes arrest at 
the G0-G1 phase.(C) PD-1 engagement regulates TCR surface expression, by promoting the 
expression of E3 ubiquitin ligases that ubiquitylate TCR chains. As a result, TCR is removed 
from the T cell surface, possibly by endocytosis. (D) Engaged PD-1 alters T cell metabolism 
by inhibition of ERK and PI3K-AKT activities. 
 
PD-1 is expressed on a large proportion of tumor-infiltrating lymphocytes 
(TILs) from many different tumor types. Among CD4+ TILs, a generally high 
level of PD-1 expression is detectable on Treg cells, which can represent a 
large proportion of intratumoral CD4+ T cells. Increased PD-1 expression on 
CD8+ TILs may either reflect an anergic or exhausted state, as has been 
suggested by decreased cytokine production by PD-1+ compared with PD-1– 
TILs from melanomas (Ahmadzadeh et al., 2009). 
The ligands of PD-1 (PD-L1 and PD-L2) are type I transmembrane 
glycoproteins, containing IgC and IgV domains. They share about 40% of 
amino acid identity. PD-Ls have distinct expression patterns: PD-L1 is 
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constitutively expressed on T and B cells, DCs, macrophages, mesenchymal 
stem cells and bone marrow-derived mast cells (Yamaki et al., 2002). In 
addition, PD-L1 is expressed on a wide variety of non-hematopoietic cells. In 
contrast, PD-L2 expression is restricted to activated DCs, macrophages, bone 
marrow derived mast cells, and more than 50% of peritoneal B1 cells. 
 
Just as PD-1 is highly expressed on TILs from many cancers, the PD-1 
ligands are commonly upregulated on the tumor cell surface from many 
different human tumors, correlating with adverse prognosis. On cells from 
solid tumors, the major PD-1 ligand that is expressed is PD-L1. Two general 
mechanisms for the regulation of PD-L1 by tumor cells have emerged: innate 
immune resistance and adaptive immune resistance. In the first case, 
constitutive oncogenic signalling pathways in the tumor cell drive PD-L1 
expression (Parsa et al., 2007). On the contrary, in adaptive immune 
resistance, the tumor uses the natural physiology of PD-1 ligand induction 
that normally occurs to protect a tissue from infection-induced immune-
mediated damage in order to protect itself from an antitumor immune 
response. Expression of PD-L1 as an adaptive response to endogenous 
antitumor immunity can occur because PD-L1 is induced on most tumor cells 
in response to interferons (IFNs), predominantly IFNγ (Taube et al., 2012). 
 
PD-Ls mediate potent inhibitory signals after ligation with PD-1, causing a 
detrimental effect on antitumor immunity by allowing the tumor cells to 
escape immunosurveillance. 
Indeed, although the PD-1: PD-L1/L2 pathway evolved to constrain such 
autoreactive T cells and maintain peripheral tolerance, it has been shown to 
have inimical effects on antiviral and antitumor immunity. 
The hypothesis that engagement of PD-1:PD-L1 pathway might dampen 
immune responses for tumors was confirmed by the observation that 
overexpression of PD-L1 on a mouse mastocytoma cell line inhibits CD8+ T 
cell cytolytic activity through PD-1 ligation, which intensifies tumor growth 
and invasiveness (Iwai et al., 2002). 
When the PD-1/PD-L1 pathway is active in the tumor microenvironment, it 
promotes survival of cancer cells via antiapoptotic signals mediated via PD-
L1 (Dong et al., 2002) and inhibits the activation of signaling pathways, 
which are critical for survival, expansion, and differentiation of T cells that 
recognize tumor antigens. The imbalanced activation of signaling events in T 
cells results in tumor tolerance by inhibiting T effector and memory cell 
generation and promoting the differentiation of TEX and Treg cells (Bardhan et 
al., 2016). These observations taken together with the general findings of 
increased PD-1 expression by TILs and the increased PD-1 ligand expression 
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by tumor cells provided an important rationale for the capacity of antibody 
blockade of this pathway to enhance intratumoral immune responses. 
 
 
1.3.3 Antibody-mediated inhibition of co-inhibitory receptors 
The working hypothesis of immunotherapy focuses on the premise that 
targeting specific molecules within the complex immunological mechanisms 
exploited by tumor cells to evade destruction can restore the antitumor 
immune response. A deep understanding of the complex interrelationships 
between the immune system and tumor cells led to the identification of 
several specific immunotherapeutic targets. Among them, immune 
checkpoint receptors emerged as a potential target for cancer treatment. Key 
targets of immune checkpoint inhibitory pathways include CTLA-4 and PD-
1. These two immune-checkpoint receptors have been most actively studied 
in the context of clinical cancer immunotherapy. However, multiple 
additional immune checkpoints represent promising targets for therapeutic 
blockade. 
In 1996, Allison and colleagues gave the first demonstration in mouse models 
of the ability of CTLA-4 antibodies to induce therapeutic antitumor 
immunity. In vivo administration of antibodies to CTLA-4 resulted in the 
rejection of tumors, including pre-established tumors. Furthermore, this 
rejection resulted in immunity to a secondary exposure to tumor cells (Leach 
et al.,1996). These preclinical findings encouraged the production and testing 
of two fully humanized CTLA-4 antibodies, ipilimumab and tremelimumab. 
The anti-CTLA-4 monoclonal antibodies (mAbs) ipilimumab, a fully human 
IgG1 (BristolMyers Squibb), and tremelimumab, a fully human IgG2 (Pfizer, 
MedImmune), were the first immune checkpoint blocking drugs to enter 
clinical testing in oncology, in 2000. In 2011, ipilimumab was approved in 
the US and Europe as first-line therapy for advanced unresectable melanoma, 
based on results from two phase III trials showing significant extensions in 
overall survival (OS) (Hodi et al., 2010; Robert et al., 2011). On the contrary, 
tremelimumab showed promise in early-phase melanoma trials, but it did not 
meet its designated endpoint when randomized against standard 
chemotherapy in a first-line phase III melanoma trial (Ribas et al., 2013). 
Antibody blockade of CTLA-4/B7 interactions is thought to promote Teff 
activation by interfering with negative signals transmitted by CTLA-4 
engagement. Furthermore, these drugs have recently been postulated to have 
unique functions endowed by their specific isotypes, with evidence 
suggesting that ipilimumab may deplete Treg cells over-expressing CTLA-4 
(Selby et al., 2013). 
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Information garnered from trials of anti-CTLA-4 agents fast-forwarded the 
development of drugs blocking PD-1 or its major ligand, PD-L1. As 
predicted by murine models, these drugs have heightened tumor selectivity 
and reduced toxicity compared to anti-CTLA-4.A number of antibodies that 
disrupt the PD-1 axis have entered clinical trials (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Statistics representative of number of clinical trials for PD-1 and PD-L1 
inhibitor with highlight on currently for FDA approved PD-1/PDL-1 inhibitors (from 
Alsaab et al., 2017). 
.  
PD-1 is more broadly expressed than CTLA-4. Its expression is also induced 
on activated non-T lymphocyte subsets, including B cells and natural killer 
(NK) cells. Therefore, although PD-1 blockade is typically viewed as 
enhancing the activity of effector T cells in tissues and in the tumor micro-
environment, it also probably enhances NK cell activity in tumors and tissues 
and may also enhance antibody production either indirectly or through direct 
effects on PD-1+ B cells. Furthermore, similarly to CTLA-4, PD-1 is highly 
expressed on Treg cells. Because many tumors are highly infiltrated with Treg 
cells that probably further suppress effector immune responses, blockade of 
the PD-1 pathway may also enhance antitumor immune responses by 
diminishing the number and/or suppressive activity of intratumoural Treg cells 
(Pardoll et al., 2012). 
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In considering that many tumor cells express multiple inhibitory ligands, and 
TILs express multiple inhibitory receptors that regulate immune responses at 
different levels and by different mechanisms, it is rational to consider that 
concurrent or sequential combination of immunotherapies maybe more 
effective than monotherapy. These considerations led to the design of 
combinatorial strategies based on the dual or triple blockade of immune 
checkpoints in order to enhance antitumor immunity. 
One such approach investigated co-targeting of PD-1 and CTLA-4. 
Preclinical models have shown that dual blockade, as compared with 
blockade of either pathway alone, synergistically improves antitumor 
responses. In clinics, combined immune checkpoint blockade (ICB) provided 
unprecedented efficacy gains innumerous cancer indications, with PD-1 
inhibitor nivolumab plus CTLA-4 inhibitor ipilimumab in advanced 
melanoma as first-ever approved therapies for combined ICB. 
However, combined ICB has considerable toxicity. Thus, gains in efficacy 
must be balanced against a higher frequency and severity of adverse drug 
reactions (ADR), therefore close monitoring and high experience in diagnosis 
and treatment of ADR is necessary (Hassel et al., 2017). 
 
 
1.4 Neo-antigens as cancer immunotherapy targets 
 
1.4.1  Tumor neo-antigens 
All tumors arise because of somatically acquired changes in the DNA of 
cancer cells. However, among all the somatic abnormalities present in a 
cancer genome some of them are triggers of cancer development, while some 
others have no contribution in carcinogenesis. To embody this concept, the 
terms 'driver' and 'passenger' mutations have been coined.  
A driver mutation is causally implicated in oncogenesis. It commonly occurs 
in genes that directly regulate the cell cycle or apoptosis. This class includes 
inactivating mutations in tumor suppressor genes and activating mutations in 
oncogenes that confer a selective advantage to the cells that carry them.On 
the contrary, passenger mutations are found within cancer genomes because 
somatic mutations without functional consequences often occur during cell 
division. They are neutral with respect to cell division or death, conferring no 
clonal growth advantage and therefore they do not contribute to cancer 
development (Stratton et al., 2009). 
A significant subset of passenger mutations results in neo-antigens: mutated 
self-peptides expressed, processed and displayed by MHC proteins on the 
surface of the malignant cells, and subsequently recognized by autologous T 
cells as ‘non-self’ antigens. Because normal tissues do not possess these 
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somatic mutations, neo-antigen-specific T cells are not subject to central and 
peripheral tolerance, and lack the ability to induce normal tissue destruction. 
As a result, neo-antigens appear to represent ideal targets for T cell-based 
cancer immunotherapy. 
The majority of relevant cancer somatic mutations are non-synonymous 
single nucleotide variants (SNVs) which change the amino acid translated by 
the respective codon. Other types of relevant mutations are insertions and 
deletions (indels), gene fusions and mutations in splice donor or acceptor 
sites of the open reading frame (ORF) of the resulting mRNA. Thereby, shifts 
may occur in the ORF and give rise to longer neo-antigen stretches harboring 
multiple immune recognition motifs (Vormehr et al., 2016). 
 
A single altered amino acid may affect T-cell recognition in three ways 
(Figure 9):  
o by creating an anchor amino acidby which the peptide acquires the ability 
to bind to an MHC molecule (Duan et al.2014); 
o (II) by changing the T-cell receptor (TCR) binding properties resulting in 
a conformationally altered MHC-peptide complex, which is recognized by 
a different T cell clone not affected by central tolerance (Yadav et al. 
2014)  
o (III) by altering processing of the respective protein and its routing 
through MHC loading compartments, e.g. an altered proteasomal cleavage 
site preserving a ligand which normally would be degraded (Spierings et 
al., 2003, Pierce at al., 2001). 
 
 
 
Figure 9. SNVs introduce neo-antigens through distinct mechanisms.  
Mutations affecting anchor positions (I) or TCR facing residues (II) can create neo-antigens. 
Furthermore, novel epitopes can occur if a mutation alters the processing of a protein or the 
transport of a peptide into the ER (III). 
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1.4.2 Personalized cancer vaccines targeting the cancer mutanome 
Neo-antigens represent potent targets for cancer immunotherapy vaccines, as 
they differentiate cancer from normal cells and can potentially be recognized 
as ‘mutated self-antigens’ by the mature T-cell repertoire, escaping central 
immune tolerance. Their systematic targeting by vaccine approaches, 
however, has been hampered by the fact that every patient’s tumor possesses 
a unique set of mutations (‘the mutanome’) that must first be identified. 
Indeed, it is now appreciated that cancer is a patient-specific disease, where 
no two tumors are alike.  
With the development of deep-sequencing technologies, it has become 
feasible to identify the mutations present within the protein-encoding part of 
the genome (the exome) of an individual tumor with relative ease. However, 
only a very small fraction of the non-synonymous mutations in expressed 
genes leads to the formation of a neo-antigen for which CD4+ or CD8+ T cell 
reactivity can be detected within tumor-infiltrating lymphocytes. The figure 
10 depicts indeed the categories that indicate current estimates of the 
likelihood of neo-antigen formation in different tumor types, on the basis of 
their mutational load. 
 
 
Figure 10. Estimate of the neo-antigen repertoire in human cancer (from Schumacher 
and Schreiber, 2015) 
Data depict the number of somatic mutations in individual tumors. Every dot represents a 
sample while the red horizontal lines are the median numbers of mutations in the respective 
cancer types. Categories on the right indicate current estimates of the likelihood of neo-
antigen formation in different tumor types.  
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Taken this into consideration, starting from the whole exome and 
transcriptome of tumor, computational algorithms are necessary for the 
prediction of likely neo-antigens to use for a personalized therapy in the 
clinical setting (Figure 11). 
 
 
 
Figure 11. Cancer exome–based identification of neo-antigens. 
The process of identifying cancer neo-antigens for targeted cancer immunotherapy consists 
of three steps: screening, selection, and validation of the candidate neo-antigens. First, the 
whole genome/exome sequence profile is comprehensively screened to identify tumor-specific 
somatic mutations (cancer neo-antigens) by massive parallel sequencing of tumor and 
normal tissues, respectively. When available, RNA sequencing data are used to focus on 
mutations in expressed genes. Second, computational algorithms are used for predicting the 
affinity of the mutation-derived peptides with the patient’s own HLA and/or TCR. Alternative 
ways of epitope selection include “minigene” library screening and utilizing mass 
spectrometry analysis. Third, synthetic mutated peptides and wild-type peptides are used to 
validate the immunogenicity and specificity of the identified antigens by in vitro T-cell assay 
or in vivo immunization.  
 
The identification of neo-antigens based on cancer exome data has been 
documented in a variety of experimental model systems and human 
malignancies. In 2012, two independent reports in mouse models provided a 
first preclinical proof that cancer exome–based approach can be used to 
identify neo-antigens that can be recognized by T cells.  
Schreiber and colleagues demonstrated the feasibility of identifying 
spontaneously immunogenic tumor rejection antigens and their anti-tumor 
potency. Using massively parallel sequencing (MPS) and the MHC class I 
epitope prediction algorithm (IEDB algorithm), they characterized expressed 
mutations in highly immunogenic methylcholanthrene-induced sarcomas 
derived from immunodeficient Rag2-/- mice. Using class I prediction 
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algorithms, they identified mutant spectrin-β2 as a potential rejection antigen 
of the d42m1 sarcoma and validated this prediction. They also demonstrated 
that cancer immunoediting of d42m1 occurs via a T-cell-dependent 
immunoselection process that promotes outgrowth of pre-existing tumor cell 
clones lacking highly antigenic mutant spectrin-β2 and other potential strong 
antigens (Matsushita et al., 2012). 
In the same year, Castle and colleagues presented a personalized 
immunotherapy approach to target the full spectrum of an individual tumor 
mutanome. They performed MPS and used the NetMHC algorithm to 
identify target neo-antigens for designing a cancer vaccine against B16F10 
murine melanoma. They identified 962 non-synonymous somatic point 
mutations, 563 of which were actually expressed in tumor genes. They then 
selected 50 mutations for in vivo validation of immunogenicity and 
specificity, by administering either mutated or wild-type synthetic long 
peptides to the experimental mice. Approximately one third (16/50) showed 
the induction of a T-cell response, two of which were confirmed to have 
antitumor effects in both prophylactic and therapeutic settings, thereby 
qualifying mutated epitopes that include single amino acid substitutions as 
effective vaccines (Castle et al., 2012). 
In 2015, the same group performed new vaccination studies employing the 
RNA vaccine technology. By using mRNA encoding mutated peptides 
identified in three different mouse tumor models (B16F10, CT26, 4T1 cancer 
cell lines)they revealed that a significant portion of mutations (21-45%) were 
immunogenic. Surprisingly, most neo-antigens were recognized by CD4+ T 
cells (70–94%) and this subset controlled growth of advanced, highly 
aggressive mouse tumors. Building on these data they developed an in silico 
approach to extract the therapeutically effective vaccine candidates out of the 
dozens or hundreds of mutations which are typically identified by NGS 
(Kreiter et al., 2012). 
Yadav et al. employed another approach for the identification of 
immunogenic neo-antigens in two tumor cell lines of MC-38 and TRAMP-
C1 (Yadav et al.2014). They used mass spectrometry analysis combined with 
whole-exome/transcriptome sequencing. Of 1290 and 67 mutations expressed 
in MC-38 and TRAMP-C1, respectively, 170 and 6 were predicted to bind 
MHC-class I molecule by the NETMHC-3.4 algorithm. On the other hand, 
only 7 and 0, respectively, were shown to be present on the MHC-class I 
molecule by mass spectrometry. Two of the seven antigens were structurally 
predicted to be immunogenic, and both actually showed strong anti-tumor 
responses in vitro. Their study suggested that utilizing mass spectrometry, as 
another filter it is possible to reduce the burden of validation assays, which 
are extremely laborious, thereby simplifying the neo-antigen discovery 
process. 
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All the encouraging results obtained by several pre-clinical studies have 
promoted the use of personalized cancer vaccines in clinics, showing 
glimmers of success. Recently, two small clinical trials showed effective anti-
tumor activity of vaccines tailored to match a patient’s mutanome. 
 
One group, led by Catherine Wu, evaluated a personalized peptide vaccine in 
a phase I study in patients with previously untreated high-risk melanoma 
after surgical resection (Ott et al., 2017). For each person, they formulated a 
vaccine that contained up to 20 protein fragments corresponding to the 
identified tumor mutations. Of six vaccinated patients, four had no recurrence 
at 25 months after vaccination, while two with recurrent disease were 
subsequently treated with anti-PD-1 therapy and experienced complete 
tumorregression, with expansion of the repertoire of neo-antigen-specific T 
cells. Indeed, they demonstrated that vaccination with neo-antigens both 
expands pre-existing neo-antigen-specific T-cell populations and induces a 
broader repertoire of new T-cell specificities in cancer patients, tipping the 
intratumoral balance in favor of enhanced tumor control. 
The second group, led by Ugur Sahin, treated 13 melanoma patients with the 
RNA-based poly-neo-antigen approach (Sahin et al., 2017). Ten selected 
mutations per patient were engineered into two synthetic RNAs, each 
encoding five linker-connected 27mer peptides with the mutation in position 
14 (pentatope RNAs). Eight patients who had no visible tumors at the time of 
vaccination remained tumor-free more than a year later. The remaining five 
participants' tumors had spread by the time they received the vaccine. Two of 
the five patients with metastatic disease experienced vaccine-related 
objective responses. One of these patients had a late relapse. A third patient 
developed a complete response to vaccination in combination with PD-1 
blockade therapy. 
These studies provide a strong rationale for further development of neo-
antigens-targeted personalized cancer vaccines, alone and in combination 
with checkpoint blockade or other immunotherapies. 
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1.5 Combining neo-antigens-targeted cancer vaccines with checkpoint 
blockade  
 
Both checkpoint blockade and neo-antigens-based cancer vaccines have 
shown promising results in the context of cancer immunotherapy but 
sometimes as monotherapy, they both revealed ineffective as anti-tumor 
treatment. Thus, a logical pursued approach has been the immunization of 
cancer patients with neo-antigens in combination with checkpoint blockade. 
Several distinct supporting data have connected checkpoint blockade and 
cancer neo-antigens. Gubin and colleagues, who identified two biologically 
active neo-antigens in a mouse sarcoma, observed that used together, the two 
neo-antigens induced tumor rejection as efficiently as checkpoint blockade 
therapy (Gubin et al., 2014). These two observations highlighted the 
possibility that checkpoint blockade may operate even partially through 
amplification of the T-cell responses to neo-antigens. Duan and colleagues, 
who identified several biologically active neo-antigens of mouse sarcomas, 
tested the activity of a neo-antigen alone, CTLA-4 blockade alone, or both 
regimens together, and noted that the combination was significantly more 
effective than either agent alone (Duan et al., 2014). 
Moreover, van Rooij and colleagues analyzed the tumor exome of a 
melanoma patient who had responded to CTLA-4 blockade and reported that 
T-cell response to a neo-antigen had increased significantly after CTLA-4 
blockade (van Rooij et al., 2013). 
Of note, two remarkable independent studies showed that the mutational 
landscape of a tumor determines sensitivity to checkpoints blockade. Starting 
from the malignant melanoma exomes of patients treated with CTLA-4 
blockade, Snyder and colleagues elucidated a neo-antigens landscape that is 
specifically present in tumors with a strong response to CTLA-4 blockade. 
They validated this signature in a second set of patients with melanoma who 
were treated with anti–CTLA-4 antibodies, showing that predicted neo-
antigens activated T cells from the patients treated with ipilimumab (Snyder 
el., 2014). Shortly afterwards, Rizvi and colleagues used whole-exome 
sequencing of non–small cell lung cancers treated with pembrolizumab to 
unravel the genomic determinants of response to this therapy. In two 
independent cohorts, higher non-synonymous mutation burden in tumors was 
associated with improved objective response, durable clinical benefit, and 
progression-free survival (Rizvi et al., 2015). 
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Taken together, all these observations suggest that exploration of synergy 
between immunotherapy with neo-antigens and checkpoint blockade might 
be productive. 
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